Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) has earned an average rating of “Moderate Buy” from the eight research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) CFO Charles N. York II sold 955 shares of the firm’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $13.12, for a total value of $12,529.60. Following the transaction, the chief financial officer now directly owns 264,798 shares […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) CEO Jeremy Bender sold 3,104 shares of the business’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $13.12, for a total value of $40,724.48. Following the completion of the transaction, the chief executive officer now directly owns 1,179,484 […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 9,120,000 shares, an increase of 16.0% from the April 15th total of 7,860,000 shares. Based on an average daily trading volume, of 778,000 […]